Heidi Greulich

发表

An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells.

Birgit Schoeberl, Andrew L. Kung, David M. Livingston, 2010, Cancer cell.

Integrative Genomic Approaches Identify IKBKE as a Breast Cancer Oncogene

Eric S. Lander, Marc Vidal, Ian F. Dunn, 2007, Cell.

Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel.

Mithat Gonen, Sarat Chandarlapaty, Neal Rosen, 2008, Cancer research.

Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions.

Laura Tolosi, Michael Peyton, Thomas Zander, 2009, The Journal of clinical investigation.

Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing

Thomas LaFramboise, Levi A Garraway, Kwok-Kin Wong, 2006, Nature Medicine.

Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation.

Martin Peifer, Daniel Rauh, Lars Ruddigkeit, 2010, Cancer research.

Identification of cancer cytotoxic modulators of PDE3A by predictive chemogenomics

Benito Munoz, Paul A Clemons, Aviad Tsherniak, 2015, Nature chemical biology.

Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants

William C Hahn, Matthew Meyerson, William R Sellers, 2005, PLoS medicine.

Drug-sensitive FGFR2 mutations in endometrial carcinoma

Kristian Cibulskis, Wendy Winckler, Michael C Zody, 2008, Proceedings of the National Academy of Sciences.

Characterizing genomic alterations in cancer by complementary functional associations

Gabriela Alexe, Chiara Romualdi, Pablo Tamayo, 2016, Nature Biotechnology.

Activating mutations in ALK provide a therapeutic target in neuroblastoma

D. Gary Gilliland, Stefan Fröhling, Wendy B. London, 2008, Nature.

Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity.

Matthew Meyerson, M. Meyerson, H. Greulich, 2007, Cancer cell.

MEDULLOBLASTOMA EXOME SEQUENCING UNCOVERS SUBTYPE-SPECIFIC SOMATIC MUTATIONS

Jill P. Mesirov, Petar Stojanov, Scott L. Pomeroy, 2012, Nature.

Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2

Wendy Winckler, Gad Getz, Steven A Carr, 2012, Proceedings of the National Academy of Sciences.

The genomics of lung adenocarcinoma: opportunities for targeted therapies.

H. Greulich, Heidi Greulich, 2010, Genes & cancer.

SNP panel identification assay (SPIA): a genetic-based assay for the identification of cell lines

Levi Garraway, Rameen Beroukhim, Mark A. Rubin, 2008, Nucleic acids research.